Dynamic Technology Lab Private Ltd Increases Holdings in Charles River Laboratories International, Inc. $CRL

Key Points

• Dynamic Technology Lab Private Ltd increased its holdings in Charles River Laboratories International by 47.3% during the first quarter, owning 7,584 shares valued at approximately $1.14 million.
• Several large investors, including Ameriprise Financial Inc and Jefferies Financial Group Inc, also boosted their stakes in Charles River Laboratories in the fourth quarter, highlighting significant institutional interest.
• Analysts have varying ratings for the stock, with some upgrades leading to a consensus price target of $175.69 and a reported earnings per share of $3.12, surpassing expectations.

Dynamic Technology Lab Private Ltd lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 47.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,584 shares of the medical research company's stock after purchasing an additional 2,434 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Charles River Laboratories International were worth $1,142,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of CRL. Ameriprise Financial Inc. boosted its holdings in shares of Charles River Laboratories International by 4.6% in the fourth quarter. Ameriprise Financial Inc. now owns 223,036 shares of the medical research company's stock valued at $41,173,000 after purchasing an additional 9,847 shares during the period. Algert Global LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $214,000. Balyasny Asset Management L.P. purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at approximately $1,052,000. Deutsche Bank AG boosted its holdings in shares of Charles River Laboratories International by 10.0% in the fourth quarter. Deutsche Bank AG now owns 232,492 shares of the medical research company's stock valued at $42,918,000 after purchasing an additional 21,151 shares during the period. Finally, Jefferies Financial Group Inc. boosted its holdings in shares of Charles River Laboratories International by 226.7% in the fourth quarter. Jefferies Financial Group Inc. now owns 17,802 shares of the medical research company's stock valued at $3,286,000 after purchasing an additional 12,353 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and boosted their price target for the company from $150.00 to $200.00 in a report on Wednesday, July 9th. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a report on Wednesday, May 14th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Finally, Wall Street Zen lowered Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 17th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and a consensus price target of $175.69.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $164.00 on Monday. The business's fifty day simple moving average is $160.62 and its 200-day simple moving average is $148.93. The company has a market cap of $8.07 billion, a PE ratio of -123.31, a PEG ratio of 5.24 and a beta of 1.47. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The business's quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 earnings per share. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of the company's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares of the company's stock, valued at approximately $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.